Erlotinib, combined with bevacizumab as a VEGFR inhibitor, showed improved clinical outcomes: 51% (25/49) and 30.6% (15/49) of patients with CC had SD and PD, respectively (ClinicalTrials.gov Identifier: NCT00356889) [126]. This evidence concerns the gene KDR and cholangiocarcinoma.